Law Firm Probes Masimo’s $180-per-Share Cash Acquisition by Danaher
Halper Sadeh LLC is investigating Masimo’s $9.9 billion sale to Danaher for $180 per share cash over potential federal securities violations and fiduciary breaches. Shareholders may seek increased consideration or additional disclosures on a contingent-fee basis with no upfront legal costs.
1. Transaction Overview
Masimo agreed to be acquired by Danaher for $180 per share in cash, valuing the transaction at approximately $9.9 billion. The deal marks one of the largest medical-technology buyouts of 2026 and was approved by Masimo’s board.
2. Legal Investigation
Halper Sadeh LLC has launched an investigation into the transaction, examining potential breaches of fiduciary duty and federal securities laws. The firm highlights that certain deal terms may restrict competing offers and could disadvantage ordinary shareholders.
3. Shareholder Rights and Remedies
Shareholders are invited to discuss their rights on a contingency-fee basis with no upfront costs. Potential outcomes include pursuing increased consideration, demanding additional disclosures or seeking other relief on behalf of Masimo investors.